Figure 2
Figure 2. Genomic and protein sequence around the mutation. (A-C) Sequence of exon 3 of CD59 around the Cys89Tyr mutation (arrow) in a patient (A), a carrier (B), and a healthy control (C). (D) Amino acid conservation around the mutation site (CD59-HS, human CD59). The region is not only conserved among the Eutheria (eg, in the CD59 protein of Pan troglodytes, CD59-PT), but also among other LY-6 domain–containing proteins in humans, including the human lymphocyte antigen 6E (LY6E), the human urokinase plasminogen activator surface receptor (PLAUR), the ly-6/neurotoxin-like protein 1 (LYNX1), and the prostate stem cell antigen (PSCA). The conserved residues are marked by an asterisk and the mutated codon by an arrow. (E) Schematic representation of the CD59 protein. The black rectangle stands for the LU domain with its multiple Cys residues (C). The site of the mutation (Cys89) of our patients is shown (arrow).

Genomic and protein sequence around the mutation. (A-C) Sequence of exon 3 of CD59 around the Cys89Tyr mutation (arrow) in a patient (A), a carrier (B), and a healthy control (C). (D) Amino acid conservation around the mutation site (CD59-HS, human CD59). The region is not only conserved among the Eutheria (eg, in the CD59 protein of Pan troglodytes, CD59-PT), but also among other LY-6 domain–containing proteins in humans, including the human lymphocyte antigen 6E (LY6E), the human urokinase plasminogen activator surface receptor (PLAUR), the ly-6/neurotoxin-like protein 1 (LYNX1), and the prostate stem cell antigen (PSCA). The conserved residues are marked by an asterisk and the mutated codon by an arrow. (E) Schematic representation of the CD59 protein. The black rectangle stands for the LU domain with its multiple Cys residues (C). The site of the mutation (Cys89) of our patients is shown (arrow).

Close Modal

or Create an Account

Close Modal
Close Modal